Abstract 621P
Background
Early detection of primary liver cancer (PLC) in patients with liver cirrhosis (LC) or chronic hepatitis virus infection (CHVI) improves survival. The urgent need is convenient and affordable tools with high sensitivity to facilitate timely diagnosis.
Methods
Tissue and plasma samples from 159 healthy individuals and 89 PLC, LC, or CHVI patients were sequenced by a targeted methylation panel (∼70,000 CpGs) to identify candidate methylated DNA markers (MDMs). In phase I, the performance of each selected MDMs was validated in 175 plasma samples (PLC, n=101; LC/CHVI, n=74) by CO-methylation aMplification rEal-Time PCR (COMET) assay. A logistic model was then trained and validated in phase II with 310 plasma samples (hepatocellular carcinoma [HCC], n=212; combined hepatocellular-cholangiocarcinoma [cHCC-CC], n=12; CHVI, n=106; training vs. validation, 2:1).
Results
The 11 selected MDMs with top performance consistently showed significant differences in tissue samples between PLC and LC/CHVI, as well as in plasma samples between PLC and LC/CHVI (P<0.05). In phase I, 8 of the above 11 MDMs with an area under the curve (AUC) over 0.80 to differentiate PLC and LC/CHVI were selected for further investigation. In phase II, the MDM-based model achieved sensitivity of 87.2% (95% confidence interval [CI], 80.8%–92.4%) and 88.0% (78.4%–94.4%), at respective specificity of 97.1% (90.1%–99.7%) and 100% (90.3%–100%) in the training and validation sets. In the validation set, sensitivity in patients with BCLC stage 0, diameter<3 cm, AFP-negative and PIVKA-II-negative was 90.0% (55.5%–99.7%), 88.9% (65.3%–98.6%), 80.6% (64.0%–91.8%), and 81.3% (54.4%–96.0%), respectively. Additionally, our model detected 19 of 24 (79.3%, 57.8%–92.9%) intrahepatic cholangiocarcinoma. Combining AFP and PIVKA-II, the model achieved higher sensitivity of 93.3% (85.1%–97.8%) and specificity of 100.0% (90.3%–100%).
Conclusions
COMET featuring low cost and high accuracy exhibits preferable potential for PLC detection in patients with LC or CHVI. Further validation in a prospective cohort is warranted.
Clinical trial identification
NCT05996666, release date 08/10/2023.
Editorial acknowledgement
Legal entity responsible for the study
Tian Yang.
Funding
National Natural Science Foundation of China (No: 81972726 and 82273074), Dawn Project Foundation of Shanghai (No: 21SG36), Shanghai Health Academic Leader Program (No. 2022XD001).
Disclosure
X. Zhu, L. Zhang, Q. You, J. Xu, Y. Xu, H. Lu, B. Li, G. Wang, S. Cai: Financial Interests, Personal, Full or part-time Employment: Burning Rock Biotech. All other authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract